Article
Biochemistry & Molecular Biology
Charlotte Dubois, Kateryna Kondratska, Artem Kondratskyi, Angela Morabito, Lina Mesilmany, Valerio Farfariello, Robert-Alain Toillon, Nathalie Ziental Gelus, Emilie Laurenge, Fabien Vanden Abeele, Loic Lemonnier, Natalia Prevarskaya
Summary: Changes in cytosolic free Ca2+ concentration play a central role in cellular processes. ORAI3 channels are expressed in both normal and pancreatic ductal adenocarcinoma cell lines, affecting store-operated calcium entry (SOCE). Silencing ORAI3 increases SOCE in PDAC cell lines and decreases SOCE in normal pancreatic cell line, impacting proliferation, cell cycle, viability, mitotic catastrophe, and cell death.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
(2021)
Article
Biotechnology & Applied Microbiology
Huiyang Wang, Wenxiu Ding, Hongwei Shi, Haiwei Bao, Yuting Lu, Tian an Jiang
Summary: The combination therapy of low-frequency ultrasound-stimulated microbubbles (USMB) and radiofrequency ablation (RFA) showed significant inhibition on Panc02 cell proliferation, migration capability, and tumor size in xenograft mice, resulting in improved survival rates. Additionally, the therapy facilitated apoptosis and autophagy of tumor cells, indicating synergistic anti-tumor efficacies.
Article
Pharmacology & Pharmacy
L. Shi, J. Wen, W. Zhang, F-D Meng, Y. Wan, L. Wang, L. Zhang, H-Y Zhu
Summary: The combination therapy of IL-15 with Met showed significant inhibitory effects on Panc02 cell proliferation, promoting apoptosis and autophagy while suppressing Akt/mTOR/STAT3 signaling transduction, leading to synergistic anti-tumor efficacy in the Panc02-bearing mouse model.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Article
Multidisciplinary Sciences
Florentina Cojocaru, Tudor Selescu, Dan Domocos, Luminita Marutescu, Gabriela Chiritoiu, Nicoleta-Raluca Chelaru, Simona Dima, Dan Mihailescu, Alexandru Babes, Dana Cucu
Summary: This study reveals the endogenous expression of TRPA1 channels in human pancreatic adenocarcinoma cell lines and provides insights into the function of the TRPA1 protein, showing that different cell lines isolated from PDAC patients had varying levels of TRPA1 expression. Activation of TRPA1 by AITC in Panc-1 cells induced non-selective cationic currents, inhibited by the TRPA1 antagonist A-967079, and led to increased intracellular Ca2+ levels. siRNA-induced downregulation of TRPA1 enhanced cell migration, suggesting a role of ion channels independent of pore function, and TRPA1 activation altered cell cycle progression.
SCIENTIFIC REPORTS
(2021)
Article
Biology
Abigail Cunningham, Maddisen Brown, Jonathan Dresselhuis, Nicole Robinson, Keni Hervie, Michael E. Cox, Julia Mills
Summary: This study investigates a novel cancer drug combination strategy targeting glioblastoma cells. The results demonstrate that combination drug treatment significantly increases cell death and aberrant mitotic division, compared to individual inhibitors.
Article
Biochemistry & Molecular Biology
Ella Rimmer, Sadaf Rashid, Igor Kraev, Francesc Miralles, Androulla Elia
Summary: Pancreatic cancer cells release extracellular vesicles that confer resistance to gemcitabine and TRAIL treatment. Removal of these vesicles during treatment may improve the response of pancreatic cancer cells to gemcitabine and TRAIL.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Sharavan Ramachandran, Itishree S. Kaushik, Sanjay K. Srivastava
Summary: Pimavanserin, as a novel anti-psychotic drug, shows potential as a treatment option for pancreatic cancer by suppressing the growth of pancreatic tumors through inducing autophagy-mediated apoptosis. The study found that Pimavanserin treatment led to increased autophagy and apoptosis in pancreatic ductal adenocarcinoma cells, supporting its role in tumor growth suppression.
Article
Medicine, Research & Experimental
Ya'an Kang, Jenying Deng, Jianhua Ling, Xinqun Li, Yi-Ju Chiang, Eugene J. Koay, Huamin Wang, Jared K. Burks, Paul J. Chiao, Mark W. Hurd, Manoop S. Bhutani, Jeffrey H. Lee, Brian R. Weston, Anirban Maitra, Naruhiko Ikoma, Ching-Wei D. Tzeng, Jeffrey E. Lee, Ronald A. DePinho, Robert A. Wolff, Shubham Pant, Florencia McAllister, Matthew H. G. Katz, Jason B. Fleming, Michael P. Kim
Summary: An organoid-based platform was developed to personalize PDAC therapy by quantifying PDO responses to drug treatments and evaluating tumor-stroma modulation.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Oncology
Juan Yang, Yin Li, Xiao Han, Xiaolin Pei, Zhoujun Lin, Chenggang Li
Summary: The study demonstrated that ACT001 has great potential in the treatment of pancreatic ductal adenocarcinoma (PDAC) by regulating the EGFR-Akt-Bim signaling pathway.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Da Eun Lee, Hyeon Woong Kang, So Yi Kim, Myeong Jin Kim, Jae Woong Jeong, Woosol Chris Hong, Sungsoon Fang, Hyung Sun Kim, Yun Sun Lee, Hyo Jung Kim, Joon Seong Park
Summary: This study demonstrates that the combination of ivermectin and gemcitabine effectively suppresses pancreatic cancer by inhibiting cell proliferation and inducing cell apoptosis through cell cycle arrest and mitochondrial dysfunction. In vivo experiments also support the tumor-inhibiting effect of this combination treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
M. Suleimenov, S. Bekbayev, M. Ten, N. Suleimenova, M. Tlegenova, A. Nurmagambetova, S. Kauanova, I. Vorobjev
Summary: Microtubule-targeting drugs taxanes and vinca alkaloids have been widely used in chemotherapy due to their ability to block mitotic progression. This study determined the maximal and minimal doses of mitotic inhibitors that cells can tolerate and showed that cell death during mitotic arrest and after slippage proceed via mitochondria-dependent apoptosis.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Eric M. Anderson, Shant Thomassian, Jun Gong, Andrew Hendifar, Arsen Osipov
Summary: Pancreatic cancer, with its highly immunosuppressive tumor microenvironment and dense stroma, presents challenges for traditional treatment approaches. Emerging treatment strategies have the potential to significantly improve outcomes for pancreatic cancer patients.
Article
Oncology
Kevin Christian Montecillo Gulay, Xinlian Zhang, Vasiliki Pantazopoulou, Jay Patel, Edgar Esparza, Deepa Sheik Pran Babu, Satoshi Ogawa, Jonathan Weitz, Isabella Ng, Evangeline S. Mose, Minya Pu, Dannielle D. Engle, Andrew M. Lowy, Herve Tiriac
Summary: The new drug MRTX1133 showed specific and effective anticancer activity against PDAC with KRASG12D mutations, and combination therapy with the pan-ERBB inhibitor afatinib led to tumor regression and longer survival in PDAC mouse models.
Review
Oncology
Kongyuan Wei, Thilo Hackert
Summary: Surgery is the main potential cure for pancreatic ductal adenocarcinoma, with advancements in surgical techniques and multimodal approaches. Despite low survival rates, combining surgery with adjuvant therapy can increase five-year survival to around 20%. However, pancreatic resection is complex and high-risk, with ongoing developments in minimally-invasive and robotic approaches.
Article
Cell Biology
Yanlu Xiong, Yangbo Feng, Jinbo Zhao, Jie Lei, Tianyun Qiao, Yongsheng Zhou, Qiang Lu, Tao Jiang, Lintao Jia, Yong Han
Summary: Our study confirmed that TFAP2A is highly expressed in LUAD, leading to poorer prognosis in multiple datasets. While TFAP2A is not essential for LUAD proliferation and can even inhibit it, it does promote metastasis through EMT. Additionally, TFAP2A activates PSG9 to enhance TGF-beta-triggered EMT, and the upregulation of TFAP2A in LUAD is partly due to the suppression of miR-16 family.
CELL DEATH & DISEASE
(2021)
Review
Biochemistry & Molecular Biology
Neelu Batra, Cristabelle De Souza, Jyoti Batra, Alan G. Raetz, Ai-Ming Yu
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Pharmacology & Pharmacy
Mei-Juan Tu, Zhijian Duan, Zhenzhen Liu, Chao Zhang, Richard J. Bold, Frank J. Gonzalez, Edward J. Kim, Ai-Ming Yu
MOLECULAR PHARMACOLOGY
(2020)
Review
Pharmacology & Pharmacy
Ai-Ming Yu, Young Hee Choi, Mei-Juan Tu
PHARMACOLOGICAL REVIEWS
(2020)
Article
Pharmacology & Pharmacy
Hannah Petrek, Pui Yan Ho, Neelu Batra, Mei-Juan Tu, Qianyu Zhang, Jing-Xin Qiu, Ai-Ming Yu
Summary: This study introduces a novel technology for dual-targeting of two miRNAs in NSCLC cells, showing greater efficacy in inhibiting cell growth and colony formation compared to using individual miRNAs alone. Additionally, a specific miRNA-loaded nanomedicine demonstrated the best effectiveness in controlling tumor growth in NSCLC patient-derived xenograft mouse models.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Young Hee Choi, Chao Zhang, Zhenzhen Liu, Mei-Juan Tu, Ai-Xi Yu, Ai-Ming Yu
Summary: This study developed a novel pharmacokinetic (PK)-pharmacodynamic (PD) model for assessing combination treatment by considering contributions from individual drugs, and incorporated the combination index method to define in vivo synergism accurately. The research found that sorafenib contributed more to tumor growth inhibition compared to coadministered doxorubicin, explaining previously inexplicable clinical observations. This model and strategy will have broad applications in translational research for identifying optimal dosage combinations with stronger synergy to improve therapeutic outcomes.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2021)
Editorial Material
Pharmacology & Pharmacy
Baitang Ning, Ai-Ming Yu
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Oncology
Xiong Zhang, Zenghong Huang, Junjian Wang, Zhao Ma, Joy Yang, Eva Corey, Christopher P. Evans, Ai-Ming Yu, Hong-Wu Chen
Summary: Prostate cancer is a common cancer in men with limited therapeutic options, but targeting drivers other than AR, such as RORgamma, may provide new treatment strategies. The study demonstrated that RORgamma antagonists effectively inhibit the growth of advanced prostate cancer tumors, suggesting a promising new approach for treating this aggressive disease.
Article
Biochemistry & Molecular Biology
Chengfei Liu, Cameron M. Armstrong, Shu Ning, Joy C. Yang, Wei Lou, Alan P. Lombard, Jinge Zhao, Chun-Yi Wu, Aiming Yu, Christopher P. Evans, Clifford G. Tepper, Pui-kai Li, Allen C. Gao
Summary: The use of a novel AR/AR-V7 degrader ARVib effectively degrades AR/AR-V7 protein in prostate cancer cells and attenuates AR/AR-V7 downstream target gene expression. Mechanistically, ARVib degrades AR/AR-V7 protein through the ubiquitin-proteasome pathway mediated by HSP70/STUB1 machinery modulation, which inhibits resistant prostate tumor growth and improves enzalutamide treatment both in vitro and in vivo. These findings suggest that ARVib has potential as a therapy for resistant CRPC by targeting AR/AR-V7 degradation.
Article
Pharmacology & Pharmacy
Linglong Deng, Hannah Petrek, Mei-Juan Tu, Neelu Batra, Ai-Xi Yu, Ai-Ming Yu
Summary: This study investigates the molecular and cellular mechanisms of miR-124-3p in controlling tumor metastasis by downregulating proteins critical for metastatic potential. The findings suggest that miR-124-3p therapy could inhibit cancer cell invasion and metastasis by disrupting cell structures and interactions.
ACTA PHARMACEUTICA SINICA B
(2021)
Article
Oncology
Anastasia L. Berg, Ashley Rowson-Hodel, Michelle Hu, Michael Keeling, Hao Wu, Kacey VanderVorst, Jenny J. Chen, Jason Hatakeyama, Joseph Jilek, Courtney A. Dreyer, Madelyn R. Wheeler, Ai-Ming Yu, Yuanpei Li, Kermit L. Carraway
Summary: Preventing drug resistance in cancer stem cells is crucial for improving treatment outcomes in cancer patients. This study found that cationic amphiphilic drugs can effectively target therapy-resistant cancer stem cell populations by inducing cell death through a different mechanism. This discovery has the potential to improve treatment outcomes for breast cancer patients and reduce the risk of tumor recurrence and metastasis.
Review
Pharmacology & Pharmacy
Gavin M. Traber, Ai-Ming Yu
Summary: RNA interference (RNAi) is a versatile method for regulating gene expression. Endogenous microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs) form RNA-induced silencing complexes to achieve gene regulation. RNAi-based drugs have been approved for clinical use and advancements in technology aim to improve their efficacy and safety. Chemical modifications and delivery platforms are being explored to enhance the structure, stability, and activity of RNA molecules. Novel biologic RNAi agents are also being developed for research purposes.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2023)
Article
Oncology
Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard, Leandro S. D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R. Leslie, Masuda Sharifi, Christopher P. Evans, Allen C. Gao
Summary: Next-generation antiandrogen drugs improve survival and quality of life in advanced prostate cancer patients, but resistance to these drugs is not well understood. This study found that the Wnt5a/FZD2 signaling pathway plays a critical role in promoting enzalutamide resistance, and targeting this pathway could be a potential therapy for advanced prostate cancer.
MOLECULAR CANCER THERAPEUTICS
(2022)
Review
Pharmacology & Pharmacy
Joseph M. Cronin, Ai -Ming Yu
Summary: The development of medications requires a thorough understanding of their pharmacokinetic and pharmacodynamic properties. The study of ADME gene products and their functions has been revolutionized by recombinant DNA technologies. These technologies enable the investigation of drug metabolism and disposition, as well as the study of posttranscriptional regulation of ADME genes.
DRUG METABOLISM AND DISPOSITION
(2023)
Article
Pharmacology & Pharmacy
Yixin Chen, Mei-Juan Tu, Fangwei Han, Zhenzhen Liu, Neelu Batra, Primo N. Lara, Hong -Wu Chen, Huichang Bi, Ai -Ming Yu
Summary: The research found that miR-22-3p, miR-9-5p, and miR-218-5p are antiproliferative miRNAs targeting non-small cell lung cancer (NSCLC) cells, and they inhibit folate metabolism and alter amino acid metabolism in NSCLC cells. In addition, the inhibition of glucose uptake by miR-22-3p and the reduction of serine biosynthesis from glucose by miR-9-5p and -218-5p were also confirmed. Recombinant miR-22-3p was more effective than miR-9-5p and -218-5p in inhibiting NSCLC cell respiration, glycolysis, and colony formation, without causing any toxicity.
ACTA PHARMACEUTICA SINICA B
(2023)
Article
Medicine, Research & Experimental
Peng-Cheng Li, Mei-Juan Tu, Pui Yan Ho, Neelu Batra, Michelle M. L. Tran, Jing-Xin Qiu, Theodore Wun, Primo N. Lara, Xiang Hu, Ai-Xi Yu, Ai-Ming Yu
Summary: A novel platform for in vivo fermentation production of humanized recombinant ncRNA molecules was developed, demonstrating their important roles in cellular processes and anti-tumor activities. The technology represents a unique addition to conventional technologies for basic research and drug development.
Article
Oncology
Xiaofan Pu, Chaolei Zhang, Guoping Ding, Hongpeng Gu, Yang Lv, Tao Shen, Tianshu Pang, Liping Cao, Shengnan Jia
Summary: This study demonstrated the potential utility of the sEV-miRNA d-signature in the diagnosis of PDAC via machine learning methods. A novel sEV biomarker, miR-664a-3p, was identified for the diagnosis of PDAC. It can also potentially promote angiogenesis and metastasis, provide insight into PDAC pathogenesis, and reveal novel regulators of this disease.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Jiaping Wang, Zhijuan Xu, Yanli Lai, Yanli Zhang, Ping Zhang, Qitian Mu, Shujun Yang, Yongcheng Sun, Lixia Sheng, Guifang Ouyang
Summary: This study demonstrates the significance of PD-1 in EBV-infected lymphoma cells. Silencing PD-1 enhances the tumor targeting effect of EBV-specific killer T cells on B lymphocytes and attenuates the immune escape effect.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Qiliang Peng, Jialong Tao, Yingjie Xu, Yi Shen, Yong Wang, Yang Jiao, Yiheng Mao, Yaqun Zhu, Yulong Liu, Ye Tian
Summary: This study investigates the potential role of lipid metabolism-associated genes (LMAGs) in neoadjuvant chemoradiotherapy (nCRT) and immunotherapy for rectal cancer. The results suggest that the SREBF2 gene is a highly predictive factor for nCRT in rectal cancer and is associated with favorable prognosis. SREBF2 is also closely associated with immune cell infiltration and immunotherapy-related genes.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Shiquan Li, Nan Zhang, Yongping Yang, Tongjun Liu
Summary: This study investigated the potential molecular mechanism of SPDEF in immune evasion of colorectal cancer (CRC) and found that it suppresses immune evasion by activating CCL28 through the modulation of M2 polarization of macrophages. These findings provide a new research direction and potential therapeutic target for immunotherapy in CRC.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Manas Sehgal, Soundharya Ramu, Joel Markus Vaz, Yogheshwer Raja Ganapathy, Srinath Muralidharan, Sankalpa Venkatraghavan, Mohit Kumar Jolly
Summary: This study investigates the relationship between gene expression patterns and phenotypic plasticity and heterogeneity in colorectal cancer (CRC). The results demonstrate the interconnectedness between different Consensus Molecular Subtypes (CMS) of CRC and specific phenotypes such as epithelial and mesenchymal characteristics. Additionally, the study reveals correlations between metabolic pathways and phenotypic scores, as well as between PD-L1 activity and mesenchymal phenotype. Single-cell RNA sequencing analysis further confirms the heterogeneity of different CMS subtypes. These findings have important implications for understanding CRC heterogeneity and developing targeted therapies.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Yutong Zou, Siyao Guo, Yan Liao, Weidong Chen, Ziyun Chen, Junkai Chen, Lili Wen, Xianbiao Xie
Summary: This study found that ceramide metabolism is associated with the progression and clinical outcome of osteosarcoma by analyzing data from osteosarcoma patients. The gene ST3GAL1 plays an important role in osteosarcoma, regulating the tumor immune microenvironment and affecting T cell function. It may become a new target for the treatment of osteosarcoma.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Chuanhui Chen, Mengzhi Wan, Xiong Peng, Qing Zhang, Yu Liu
Summary: This study examines the function and mechanism of the ceRNA network centered around GPR37 in LUAD. The findings show that high expression of GPR37 in LUAD tissue samples is associated with poor prognosis, and it may regulate the expression of downstream target genes by competitively binding to lncRNA DLEU1 and miR-4458.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Junping Li, Hong Hu, Jinping He, Yuling Hu, Manting Liu, Bihui Cao, Dongni Chen, Xiaodie Ye, Jian Zhang, Zhiru Zhang, Wen Long, Hui Lian, Deji Chen, Likun Chen, Lili Yang, Zhenfeng Zhang
Summary: Sequential administration of CDC7 inhibitor XL413 after carboplatin enhances the chemotherapeutic effect of carboplatin on ovarian cancer cells, possibly by inhibiting homologous recombination repair activity and increasing the accumulation of chemotherapy-induced DNA damage.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Madison Catalanotto, Joel Markus Vaz, Camille Abshire, Reneau Youngblood, Min Chu, Herbert Levine, Mohit Kumar Jolly, Ana -Maria Dragoi
Summary: The study demonstrates that loss of FLASH in cancer cells leads to a hybrid E/M phenotype with high epithelial scores, suggesting FLASH acts as a repressor of the epithelial phenotype. Additionally, FLASH expression is inversely correlated with the epithelial score and subsets of mesenchymal markers are distinctly up-regulated in FLASH, NPAT, or SLBP-depleted cells.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Xiaorui Wang, Na Li, Minying Zheng, Yongjun Yu, Shiwu Zhang
Summary: Adipocytes are derived from pluripotent mesenchymal stem cells and histone modifications play a key role in their differentiation. Recent studies have shown that cancer stem cells can differentiate into adipocytes, reducing the malignancy of cancer cells.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Hana Q. Sadida, Alanoud Abdulla, Sara Al Marzooqi, Sheema Hashem, Muzafar A. Macha, Ammira S. Al-Shabeeb Akil, Ajaz A. Bhat
Summary: Cancer heterogeneity and drug resistance are major obstacles to effective cancer treatment, and epigenetic modifications play a pivotal role in these processes. This review explores essential epigenetic modifications, including DNA methylation, histone modifications, and chromatin remodeling, and discusses their complex contributions to cancer biology. However, the interplay of epigenetic and genetic changes in cancer cells presents unique challenges that must be addressed to fully exploit the potential of epigenetic modifications.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Pedro De Marchi, Leticia Ferro Leal, Luciane Sussuchi da Silva, Rodrigo de Oliveira Cavagna, Flavio Augusto Ferreira da Silva, Vinicius Duval da Silva, Eduardo C. A. da Silva, Augusto O. Saito, Vladmir C. Cordeiro de Lima, Rui Manuel Reis
Summary: The TIS and IFN-gamma signatures are predictive biomarkers for identifying NSCLC patients who could potentially benefit from immune checkpoint inhibitor therapies.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Giovanni Marchi, Anna Rajavuori, Mai T. N. Nguyen, Kaisa Huhtinen, Sinikka Oksa, Sakari Hietanen, Sampsa Hautaniemi, Johanna Hynninen, Jaana Oikkonen
Summary: The study shows that ctDNA can adequately represent high-grade serous ovarian carcinoma (HGSC), and the mutations observed at relapse suggest personalized therapy options.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Yuncang Yuan, Jiawei Fan, Dandan Liang, Shijie Wang, Xu Luo, Yongjie Zhu, Nan Liu, Tingxiu Xiang, Xudong Zhao
Summary: This study demonstrates that csGRP78-directed CAR-T cells can selectively kill pancreatic cancer cells, and the combination with chemotherapy enhances cytotoxicity.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Niyati Piplani, Tanusri Roy, Neha Saxena, Shamik Sen
Summary: The glycocalyx, a protective barrier surrounding cells, has been found to play a role in cancer cell proliferation, survival, and metastasis. However, its function in maintaining DNA/nuclear integrity during migration through dense matrices has not been explored. This study shows that the bulkiness of the glycocalyx is inversely associated with nuclear stresses, and highlights its mechanical role in shielding migration-associated stresses.
TRANSLATIONAL ONCOLOGY
(2024)